Does the media prefer PGNY or CSTL?

In the previous week, Progyny had 7 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Progyny and 3 mentions for Castle Biosciences. Progyny's average media sentiment score of 1.07 beat Castle Biosciences' score of 0.62 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CSTL or HTFL?

In the previous week, Castle Biosciences and Castle Biosciences both had 3 articles in the media. Heartflow's average media sentiment score of 1.61 beat Castle Biosciences' score of 0.62 indicating that Heartflow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heartflow 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CSTL or AGL?

In the previous week, Agilon Health had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Agilon Health and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.62 beat Agilon Health's score of 0.25 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilon Health 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CSTL or AVAH?

In the previous week, Aveanna Healthcare had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Aveanna Healthcare and 3 mentions for Castle Biosciences. Aveanna Healthcare's average media sentiment score of 1.03 beat Castle Biosciences' score of 0.62 indicating that Aveanna Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aveanna Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CSTL or ADUS?

In the previous week, Addus HomeCare had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Addus HomeCare and 3 mentions for Castle Biosciences. Addus HomeCare's average media sentiment score of 1.00 beat Castle Biosciences' score of 0.62 indicating that Addus HomeCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Addus HomeCare 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Castle Biosciences (CSTL) Competitors

$24.68 -0.80 (-3.14%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$24.74 +0.05 (+0.22%)

As of 07/24/2026 07:34 PM Eastern

Compare

CSTL vs. PGNY, HTFL, AGL, AVAH, and ADUS

Should you buy Castle Biosciences stock or one of its competitors? MarketBeat compares Castle Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Castle Biosciences include Progyny (PGNY), Heartflow (HTFL), Agilon Health (AGL), Aveanna Healthcare (AVAH), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry.

How does Castle Biosciences compare to Progyny?

Progyny (NASDAQ:PGNY) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Progyny has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.89	$58.52M	$0.77	40.51
Castle Biosciences	$339.92M	2.20	-$24.16M	-$0.44	N/A

94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Progyny had 7 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Progyny and 3 mentions for Castle Biosciences. Progyny's average media sentiment score of 1.07 beat Castle Biosciences' score of 0.62 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny currently has a consensus price target of $32.67, indicating a potential upside of 4.73%. Castle Biosciences has a consensus price target of $42.43, indicating a potential upside of 71.91%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Progyny has a net margin of 5.23% compared to Castle Biosciences' net margin of -3.78%. Progyny's return on equity of 13.34% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Summary

Progyny beats Castle Biosciences on 14 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Heartflow?

Castle Biosciences (NASDAQ:CSTL) and Heartflow (NASDAQ:HTFL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Castle Biosciences has a net margin of -3.78% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Heartflow	-58.42%	N/A	-20.02%

Castle Biosciences has higher revenue and earnings than Heartflow. Castle Biosciences is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$339.92M	2.20	-$24.16M	-$0.44	N/A
Heartflow	$191.42M	10.87	-$116.79M	-$3.11	N/A

Castle Biosciences currently has a consensus price target of $42.43, suggesting a potential upside of 71.91%. Heartflow has a consensus price target of $37.00, suggesting a potential upside of 53.40%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

92.6% of Castle Biosciences shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 7.7% of Heartflow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Castle Biosciences and Castle Biosciences both had 3 articles in the media. Heartflow's average media sentiment score of 1.61 beat Castle Biosciences' score of 0.62 indicating that Heartflow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heartflow	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Castle Biosciences beats Heartflow on 9 of the 14 factors compared between the two stocks.

How does Castle Biosciences compare to Agilon Health?

Castle Biosciences (NASDAQ:CSTL) and Agilon Health (NYSE:AGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Castle Biosciences has a net margin of -3.78% compared to Agilon Health's net margin of -6.09%. Castle Biosciences' return on equity of -2.77% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Agilon Health	-6.09%	-146.03%	-24.55%

Castle Biosciences has higher earnings, but lower revenue than Agilon Health. Castle Biosciences is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$339.92M	2.20	-$24.16M	-$0.44	N/A
Agilon Health	$5.82B	0.28	-$391.35M	-$21.56	N/A

Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Agilon Health has a beta of 2.98, meaning that its stock price is 198% more volatile than the broader market.

Castle Biosciences presently has a consensus price target of $42.43, suggesting a potential upside of 71.91%. Agilon Health has a consensus price target of $66.50, suggesting a potential downside of 32.03%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Castle Biosciences is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Agilon Health	3 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14

92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 2.5% of Agilon Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Agilon Health had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Agilon Health and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.62 beat Agilon Health's score of 0.25 indicating that Castle Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilon Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Castle Biosciences beats Agilon Health on 13 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Aveanna Healthcare?

Castle Biosciences (NASDAQ:CSTL) and Aveanna Healthcare (NASDAQ:AVAH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Aveanna Healthcare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$339.92M	2.20	-$24.16M	-$0.44	N/A
Aveanna Healthcare	$2.52B	0.82	$225.03M	$1.18	8.01

Aveanna Healthcare has a net margin of 10.37% compared to Castle Biosciences' net margin of -3.78%. Aveanna Healthcare's return on equity of 124.68% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Aveanna Healthcare	10.37%	124.68%	7.07%

Castle Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Aveanna Healthcare has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Castle Biosciences currently has a consensus price target of $42.43, suggesting a potential upside of 71.91%. Aveanna Healthcare has a consensus price target of $10.78, suggesting a potential upside of 14.05%. Given Castle Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Castle Biosciences is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aveanna Healthcare had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Aveanna Healthcare and 3 mentions for Castle Biosciences. Aveanna Healthcare's average media sentiment score of 1.03 beat Castle Biosciences' score of 0.62 indicating that Aveanna Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aveanna Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aveanna Healthcare beats Castle Biosciences on 10 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Addus HomeCare?

Castle Biosciences (NASDAQ:CSTL) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 4.1% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Addus HomeCare has a net margin of 6.89% compared to Castle Biosciences' net margin of -3.78%. Addus HomeCare's return on equity of 9.80% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Addus HomeCare	6.89%	9.80%	7.34%

Castle Biosciences presently has a consensus price target of $42.43, suggesting a potential upside of 71.91%. Addus HomeCare has a consensus price target of $131.50, suggesting a potential upside of 14.80%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Castle Biosciences is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Addus HomeCare had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 5 mentions for Addus HomeCare and 3 mentions for Castle Biosciences. Addus HomeCare's average media sentiment score of 1.00 beat Castle Biosciences' score of 0.62 indicating that Addus HomeCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Addus HomeCare	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Addus HomeCare has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$339.92M	2.20	-$24.16M	-$0.44	N/A
Addus HomeCare	$1.42B	1.50	$95.91M	$5.41	21.17

Summary

Addus HomeCare beats Castle Biosciences on 10 of the 15 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$772.81M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-56.09	21.48	27.14	23.64
Price / Sales	2.20	170.08	517.08	89.50
Price / Cash	22.89	157.90	50.54	59.64
Price / Book	1.53	7.88	10.28	6.07
Net Income	-$24.16M	$23.86M	$3.60B	$331.99M
7 Day Performance	2.15%	-3.82%	-1.27%	-0.63%
1 Month Performance	7.73%	-2.61%	-0.37%	-2.00%
1 Year Performance	53.58%	32.79%	18.30%	13.62%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	3.6299 of 5 stars	$24.68 -3.1%	$42.43 +71.9%	+50.2%	$772.81M	$339.92M	N/A	540	Upcoming Earnings
PGNY Progyny	3.3488 of 5 stars	$32.32 +1.1%	$30.73 -4.9%	+35.6%	$2.53B	$1.29B	41.97	310	News Coverage Positive News Analyst Forecast Gap Up
HTFL Heartflow	3.1354 of 5 stars	$25.56 -2.3%	$37.00 +44.8%	N/A	$2.20B	$176.03M	N/A	699	News Coverage Positive News
AGL Agilon Health	0.9118 of 5 stars	$124.49 +7.5%	$64.00 -48.6%	+88.6%	$2.08B	$5.93B	N/A	1,076	News Coverage Analyst Downgrade
AVAH Aveanna Healthcare	4.6311 of 5 stars	$9.32 -3.6%	$10.78 +15.6%	+139.8%	$2.03B	$2.43B	7.89	35,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. PGNY, HTFL, AGL, AVAH, and ADUS

How does Castle Biosciences compare to Progyny?

Summary

How does Castle Biosciences compare to Heartflow?

Summary

How does Castle Biosciences compare to Agilon Health?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. PGNY, HTFL, AGL, AVAH, and ADUS

How does Castle Biosciences compare to Progyny?

Which has more volatility and risk, PGNY or CSTL?

Which has higher earnings and valuation, PGNY or CSTL?

Do insiders & institutionals believe in PGNY or CSTL?

Does the media prefer PGNY or CSTL?

Do analysts prefer PGNY or CSTL?

Is PGNY or CSTL more profitable?

Summary

How does Castle Biosciences compare to Heartflow?

Is CSTL or HTFL more profitable?

Which has better earnings & valuation, CSTL or HTFL?

Do analysts rate CSTL or HTFL?

Do insiders & institutionals have more ownership in CSTL or HTFL?

Does the media refer more to CSTL or HTFL?

Summary

How does Castle Biosciences compare to Agilon Health?

Is CSTL or AGL more profitable?

Which has stronger valuation & earnings, CSTL or AGL?

Which has more risk and volatility, CSTL or AGL?

Do analysts prefer CSTL or AGL?

Do institutionals & insiders hold more shares of CSTL or AGL?

Does the media refer more to CSTL or AGL?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Which has stronger valuation and earnings, CSTL or AVAH?

Is CSTL or AVAH more profitable?

Which has more risk and volatility, CSTL or AVAH?

Do analysts rate CSTL or AVAH?

Do insiders & institutionals believe in CSTL or AVAH?

Does the media favor CSTL or AVAH?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Do insiders and institutionals hold more shares of CSTL or ADUS?

Is CSTL or ADUS more profitable?

Do analysts recommend CSTL or ADUS?

Does the media favor CSTL or ADUS?

Which has more volatility and risk, CSTL or ADUS?

Which has better valuation & earnings, CSTL or ADUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools